Are tougher EU regulations killing innovation and driving firms away?
This article was originally published in Clinica
There will soon be little incentive for medical device companies to develop and launch innovative devices in Europe. The regulatory hurdles are growing higher and higher, while those in the US are lowering.
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
In second letter this year targeting email communications, OPDP says that putting the methotrexate oral solution’s risk information below the signature block does not offer ‘prominence and readability’ comparable to the information on the drug’s effectiveness for the treatment of acute lymphoblastic leukemia that was in the body of the email.